Sermorelin timeline: what research and user reports show

Sermorelin is a GHRH(1-29) fragment with a long history in pediatric growth-hormone deficiency diagnosis and treatment. Adult, off-label use for sleep and recovery has far less controlled data behind it, which is worth holding onto when reading any adult timeline.

Weeks 1 to 2: early reports

Mild flushing, headache or dizziness are the most commonly reported early notes. Sleep quality is generally the first change people report, consistent with GHRH's role in slow-wave sleep.

Weeks 3 to 12: where slower changes are reported

Fluid retention or mild joint discomfort is sometimes reported as growth-hormone activity builds, generally described as settling with continued use. Body-composition changes, where reported, are described as gradual rather than an early or sudden shift.

Common questions

Why is adult evidence thinner than for children? The approved use case is pediatric growth-hormone deficiency diagnosis and treatment, and adult anti-aging or recovery use is off-label with comparatively little controlled data.

For mechanism, dosing reference and citations, see the Sermorelin reference page.